The idea of combining SMAD4 loss with other biomarkers expression was tackled in a study by De Kruijf et al. combining SMAD4 loss with the expression of TGFβ type I & II receptors that could identify a subgroup of stage I to III breast cancer carrying the poorest outcome [29]. Here, TGFB1 is linked to breast carcinoma.